Amgen is a pioneer in developing value-based contracts to help improve patient access to innovative medicines and offer system stakeholders greater budget predictability and risk-sharing.
We collaborate with payers, PBMs, health plans, and other stakeholders to help improve patient access to medicines.
- Amgen remains a leader in value-based contracts with more than 120 globally
- Amgen has a number of value-based contracts in the U.S. with a variety of commercial payers
We believe value-based contracts provide a valuable option to payers interested in evolving from volume-based contracts to those focused on the value medicines can bring to patients.